Samalin Investment Counsel LLC Sells 1,015 Shares of Amgen Inc. (NASDAQ:AMGN)

Samalin Investment Counsel LLC decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 24.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,169 shares of the medical research company's stock after selling 1,015 shares during the period. Samalin Investment Counsel LLC's holdings in Amgen were worth $826,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of AMGN. Centricity Wealth Management LLC purchased a new position in shares of Amgen during the 4th quarter worth approximately $25,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen during the third quarter valued at approximately $29,000. Synergy Investment Management LLC purchased a new stake in Amgen in the fourth quarter worth $34,000. Atala Financial Inc bought a new position in Amgen in the fourth quarter worth $34,000. Finally, Heck Capital Advisors LLC purchased a new position in Amgen during the fourth quarter valued at $36,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Stock Performance

Shares of AMGN stock traded up $0.96 on Thursday, reaching $306.67. The stock had a trading volume of 187,810 shares, compared to its average volume of 2,536,202. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The stock has a market cap of $164.75 billion, a P/E ratio of 40.62, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The company has a 50 day simple moving average of $299.66 and a 200 day simple moving average of $298.46.

Remove Ads

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.10%. Amgen's dividend payout ratio is currently 126.09%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AMGN. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Amgen in a research report on Wednesday, February 5th. StockNews.com cut shares of Amgen from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Leerink Partners lowered their target price on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Royal Bank of Canada reissued an "outperform" rating and issued a $324.00 price target on shares of Amgen in a research report on Friday, January 24th. Finally, Bank of America raised their price objective on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Amgen currently has an average rating of "Hold" and an average price target of $314.04.

Insiders Place Their Bets

In related news, EVP David M. Reese sold 25,225 shares of the firm's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the transaction, the executive vice president now directly owns 36,922 shares of the company's stock, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares of the company's stock, valued at $8,496,669.44. This represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,341 shares of company stock worth $20,644,335. Company insiders own 0.69% of the company's stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.